Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort.

Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA.

Fertil Steril. 2013 Dec;100(6):1660-6. doi: 10.1016/j.fertnstert.2013.08.008. Epub 2013 Sep 5.

2.

Ovarian cancer risk after the use of ovulation-stimulating drugs.

Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL.

Obstet Gynecol. 2004 Jun;103(6):1194-203.

PMID:
15172852
3.

Long-term relationship of ovulation-stimulating drugs to breast cancer risk.

Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Ruggieri D, Trabert B, Lamb EJ.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):584-93. doi: 10.1158/1055-9965.EPI-13-0996.

4.

Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility.

Skalkidou A, Sergentanis TN, Gialamas SP, Georgakis MK, Psaltopoulou T, Trivella M, Siristatidis CS, Evangelou E, Petridou E.

Cochrane Database Syst Rev. 2017 Mar 25;3:CD010931. doi: 10.1002/14651858.CD010931.pub2. Review.

PMID:
28349511
5.

Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study.

Bjørnholt SM, Kjaer SK, Nielsen TS, Jensen A.

Hum Reprod. 2015 Jan;30(1):222-31. doi: 10.1093/humrep/deu297. Epub 2014 Nov 5.

PMID:
25376453
6.

Use of fertility drugs and risk of ovarian cancer.

Diergaarde B, Kurta ML.

Curr Opin Obstet Gynecol. 2014 Jun;26(3):125-9. doi: 10.1097/GCO.0000000000000060. Review.

7.

Effects of fertility drugs on cancers other than breast and gynecologic malignancies.

Brinton LA, Moghissi KS, Scoccia B, Lamb EJ, Trabert B, Niwa S, Ruggieri D, Westhoff CL.

Fertil Steril. 2015 Oct;104(4):980-988. doi: 10.1016/j.fertnstert.2015.06.045. Epub 2015 Jul 29.

8.

Clomiphene citrate versus high doses of gonadotropins for in vitro fertilisation in women with compromised ovarian reserve: a randomised controlled non-inferiority trial.

Ragni G, Levi-Setti PE, Fadini R, Brigante C, Scarduelli C, Alagna F, Arfuso V, Mignini-Renzini M, Candiani M, Paffoni A, Somigliana E.

Reprod Biol Endocrinol. 2012 Dec 18;10:114. doi: 10.1186/1477-7827-10-114.

9.

Fertility drug use and risk of ovarian tumors: a debated clinical challenge.

Gadducci A, Guerrieri ME, Genazzani AR.

Gynecol Endocrinol. 2013 Jan;29(1):30-5. doi: 10.3109/09513590.2012.705382. Epub 2012 Sep 5. Review.

PMID:
22946709
10.

Infertility, ovulation induction treatments and the incidence of breast cancer--a historical prospective cohort of Israeli women.

Lerner-Geva L, Keinan-Boker L, Blumstein T, Boyko V, Olmar L, Mashiach S, Rabinovici J, Potashnik G, Lunenfeld E, Schenker JG, Shushan A, Fishman A, Cohen I, Vagman I, Lunenfeld B.

Breast Cancer Res Treat. 2006 Nov;100(2):201-12. Epub 2006 May 10.

PMID:
16685587
11.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.

Turan V, Bedoschi G, Moy F, Oktay K.

Fertil Steril. 2013 Dec;100(6):1681-5.e1. doi: 10.1016/j.fertnstert.2013.08.030. Epub 2013 Sep 19.

12.

Uterine cancer after use of clomiphene citrate to induce ovulation.

Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, Brinton LA.

Am J Epidemiol. 2005 Apr 1;161(7):607-15.

PMID:
15781949
13.
14.

Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics.

Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Haisonleder D, Krawetz SA, Barnhart K, Trussell JC, Jin Y, Santoro N, Eisenberg E, Zhang H; National Institute of Child Health and Human Development (NICHD) Reproductive Medicine Network.

Fertil Steril. 2015 Apr;103(4):962-973.e4. doi: 10.1016/j.fertnstert.2014.12.130. Epub 2015 Feb 20.

15.

Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort.

Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Trabert B, Niwa S, Moghissi KS.

Hum Reprod. 2013 Oct;28(10):2813-21. doi: 10.1093/humrep/det323. Epub 2013 Aug 13.

16.

In vitro fertilisation for unexplained subfertility.

Pandian Z, Gibreel A, Bhattacharya S.

Cochrane Database Syst Rev. 2015 Nov 19;(11):CD003357. doi: 10.1002/14651858.CD003357.pub4. Review.

PMID:
26583517
17.

Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Rizzuto I, Behrens RF, Smith LA.

Cochrane Database Syst Rev. 2013 Aug 13;(8):CD008215. doi: 10.1002/14651858.CD008215.pub2. Review.

PMID:
23943232
18.

Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden.

Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I.

Fertil Steril. 2009 Apr;91(4):1152-8. doi: 10.1016/j.fertnstert.2008.01.073. Epub 2008 Apr 18.

PMID:
18371964
19.

Ovarian stimulation and risk of breast cancer in Swedish women.

Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Bergh C, Gemzell-Danielsson K, Johansson ALV.

Fertil Steril. 2017 Jul;108(1):137-144. doi: 10.1016/j.fertnstert.2017.05.010. Epub 2017 Jun 7.

20.

Supplemental Content

Support Center